High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is the most common first-line treatment for patients with multiple myeloma (MM) under 65 years of age. A second ASCT at first relapse is frequently used but is challenged by the use of novel drugs. We retrospectively studied the outcome of second-line treatment in MM patients from the Nordic countries with relapse after first-line HDT and ASCT. Patients that underwent a second ASCT (n = 111) were compared with patients re-treated with conventional cytotoxic drugs only (n = 91) or with regimens including novel drugs (proteasome inhibitors and/or immunomodulatory drugs) (n = 362) without a second ASCT. For patients receiving a second ASCT median overall survival was 4.0 years compared with 3.3 years (P o 0.001) for the group treated with novel drugs and 2.5 years (P o 0.001) for those receiving conventional cytotoxic drugs only. A second ASCT also resulted in a significantly longer second time to progression and a significantly longer time to next treatment. We conclude that, irrespective of the addition of novel drugs, MM patients in first relapse after ASCT still appear to benefit from a second ASCT. A second ASCT should be considered for all physically fit patients.
INTRODUCTION
Although the median overall survival (OS) in multiple myeloma (MM) has increased from about 3 years to 5 years during the last decades, the disease is still considered incurable. In spite of the appearance of numerous novel drugs-proteasome inhibitors (PI) and immunomodulatory drugs (IMiDs) 1 -almost all patients below 60-65 years of age are treated upfront with autologous stem cell transplantation (ASCT). Still almost all patients progress because of residual disease. 2, 3 However, a fraction of patients obtain long-term survival, which is frequently associated with a high quality of response to therapy. 4, 5 A CR, in particular a molecular remission, 6 following first-line treatment is associated with longer time to progression (TTP) and better survival. Allogeneic stem cell transplantation is most likely to give molecular remissions 7 but is still controversial as first-line treatment owing to higher transplantrelated mortality. 8, 9 Furthermore, only a limited number of patients are eligible for this treatment modality. Therefore high-dose chemotherapy (HDT) followed by ASCT remains the standard firstline treatment for MM patients younger than around 65 years. 10 As practically all patients relapse, despite initial HDT and ASCT, an effective second-line treatment is important and will further improve the outcome. Previous retrospective studies have indicated that a second ASCT is beneficial at relapse, at least if relapse occurs later than 18 months from initial treatment. 11 However, the development of novel drugs, for example, PI and IMiDs 1, [12] [13] [14] [15] have raised the question if a second ASCT could be replaced by these drugs in second line. [16] [17] [18] A recent prospective study has shown that HDT followed by ASCT is superior to a cyclophosphamide-based regimen but data are lacking for comparing the novel drugs to ASCT. 19 The aim of the present retrospective study was to compare the outcome following a second ASCT to re-treatment with the conventional cytotoxic drugs only, or regimens including novel drugs without ASCT, in a cohort of MM patients from the Nordic countries with relapsed disease after ASCT first line.
PATIENTS AND METHODS

Study population
Consecutive patients from 24 hospitals in Denmark, Finland, Norway and Sweden diagnosed with MM between 2000 and 2013 that had undergone ASCT as the first-line treatment (n = 1061) and received a second-line treatment during the study period (n = 564) were included. Patients with plasma cell leukemia or a solitary plasmacytoma were excluded. The patients underwent stem cell harvest prior to the first ASCT. Stem cell harvest was successful in 97% of the cases. The remaining 3% where stem cell harvest failed did not undergo any ASCT and were therefore not included in the study. The study was approved by the ethical committees in each country. Data regarding age, gender, type of myeloma, presence of bone destruction and laboratory findings (M-protein in serum and urine, free light chains, calcium, hemoglobin, β 2 -microglobulin, albumin and creatinine) were collected at the time of diagnosis. Start and stop dates for 1 each drug, type of response, TTP and to time to next treatment (TTNT) were also recorded. There were no data available on whether relapse was symptomatic or only biochemical before the second-line treatment. Date of death was collected from the medical records or respective national death registry. If the patient was lost to follow-up, the patient was censored at the date of last visit if still alive at the end of the study. Median follow-up was 5.3 years. Study design and the main treatment regimens are described in Figure 1 .
Definitions
Response to treatment was defined according to the criteria proposed by Blade et al.
14 OS was calculated from the beginning of first-line treatment until death (or censored at last follow-up) and OS2 from beginning of second-line treatment until death (or censored at last follow-up). TTP was defined as time to disease progression or death, TTP1 from start of first-line and TTP2 from start of second-line therapy. TTNT1 and TTNT2 were defined as TTP but until start of second and third-line therapy, respectively. Second-line therapies were classified in either of the three groups: (1) ASCT irrespective of the induction treatment (novel or conventional) (2) regimens including only novel drugs (PI and/or IMiDs) without ASCT and (3) regimens including only conventional chemotherapy without ASCT.
Statistical methods and data management
Statistical comparisons to test differences between two independent groups were made using the Mann-Whitney test. To evaluate hypotheses of variables in contingency tables the Fisher's Exact t-test was used. Cox regression analyzes were used to identify predictive factors and the life table curves were calculated according to Kaplan-Meier analyzes and compared using the Log-rank test. In addition, descriptive statistics were used to characterize the data. A P-value of o0.05 was considered as significant.
RESULTS
Patient characteristics
Out of the 564 patients receiving any second-line treatment after ASCT, 111 (20%) underwent a second ASCT (ASCT2), 362 (64%) were given a regimen including at least one novel drug and 91 (16%) patients received conventional chemotherapy only. Baseline patient characteristics are presented in Table 1 . No patient received or underwent a second ASCT as salvage therapy without prior re-induction. The outcome of re-induction therapy (before ASCT2) did not differ between the ASCT2 group and the novel agent group ( ⩾ PR 63% and 62%, respectively). Patients undergoing a second ASCT were younger (P o 0.001) and had lower hemoglobin (P = 0.017) compared with the other treatment groups. Patients that have been treated with upfront double HDT and ASCT were less frequently treated with a new ASCT at first relapse. The median TTNT1 for all patients was 2.3 years. The TTNT was only slightly longer (but still statistically significant P = 0.02) for the ASCT2 cohort (2.4 years) compared with the cohorts re-treated with novel agents or conventional chemotherapy only (2.3 and 2.1 years, respectively). If excluding patients with relapse within 1 year (n = 65) or 1.5 years (n = 198) the statistical difference between the treatment cohorts disappeared. Only 11/564 patients underwent an ASCT after a second relapse; 7 patients in the novel agent group (2%), 3 patients in the conventional chemotherapy only group (3%) and 1 patient in the ASCT2 group (1%). These patients were included in the statistical analyses but did not significantly influence the results.
A second ASCT gives better response quality and longer time to disease progression compared with the regimens not including ASCT The quality of response to second-line treatment for each therapy group is presented in Table 2 . The percentages of patients obtaining PR or better to second-line treatment were 92, 62 and 28%, for those receiving a second ASCT, only novel drugs or only conventional chemotherapy respectively. Patients receiving a second ASCT had significantly longer TTNT2 compared with the other treatment groups (ASCT 2.4 years, novel drug regimen 1.2 years, conventional chemotherapy 0.6 years, P = 0.004 (ASCT2/ Figure 1 . Study design and description of treatment groups. A second ASCT at relapse prolongs survival M Grövdal et al Novel) and P o0.001 (ASCT2/Conventional), respectively). Also, TTP2 was significantly longer for patients receiving a second ASCT compared with the other two groups (Table 3 , Figure 2a ). If patients with a relapse within 1 year from the start of first-line treatment were excluded the median TTNT2 was still significantly longer for the ASCT2 cohort compared with the novel drug cohort and the conventional chemotherapy group (2.3, 1.3 and 0.5 years respectively, ASCT2/novel drugs P = 0.019 and ASCT2/conventional chemotherapy P o 0.001). Median TTNT2 also differed significantly if excluding patients who relapsed within 1.5 years from the start of first line.
A second ASCT is associated with better survival compared with the non-ASCT regimens Patients who received a novel drug therapy had significantly better OS2 that those treated with convetional chemotherapy only (3.3 and 2.5 years, respectively, P = 0.026). However, a second ASCT was associated to a significantly longer OS2 also when compared with the novel drug-treated cohort (4.0 vs 3.3 years, P = 0.013; Table 3 , Figures 2b and c) . In a univariate analysis of OS2 and TTNT2 according to previously known risk factors (Table 4) , younger age, higher hemoglobin, as well as a second ASCT were associated with a significantly better OS2. Younger age, higher hemoglobin, lower β 2 -microglobulin and a second ASCT were associated with longer TTNT2. However, in a multivariate analysis only a second ASCT and higher hemoglobin levels remained associated to better OS2, whereas higher age remained negatively associated to TTNT2 (Table 5) .
If patients who had progressed within 1 year from the start of first-line treatment were excluded the median OS2 for ASCT2, novel drug and conventionally treated patients were 3.9, 3.3 and 2.5 years, (P = 0.049 (ASCT2/novel drugs) and P = 0.002 (ASCT2/ Conventional), respectively). Excluding patients who relapsed within 1.5 years (n = 198) the median OS2 for ASCT2, novel drugs and conventionally treated patients were 4.8, 4.1 and 2.6 years (P = 0.046 (ASCT2/novel drugs) and P o 0.001 (ASCT2/conventional), respectively).
DISCUSSION
In this retrospective study we investigate the outcome of the second-line treatments (a second ASCT, novel drugs without ASCT or conventional chemotherapy only) in a group of relapsed MM patients that had been treated with HDT and ASCT first line.
We found that second-line HDT followed by ASCT at relapse was superior both to regimens including novel drugs (without ASCT) and to conventional chemotherapy alone. OS as measured from the start of first-line therapy (OS1) or from the start of second-line treatment (OS2) was significantly better with ASCT. Also, time from the start of second-line treatment to next treatment (TTNT2) was superior with ASCT (Table 2 and Figures 2a and c) .
Our study population did not seem to differ significantly from relapsed MM patients in other retrospective studies. 20 We consider our data robust and representative for the whole Nordic MM population. Data were collected consecutively from hospitals in Denmark, Finland, Norway and Sweden, university hospitals, as well as regional and local hospitals. We think that this adds strength to our results as they represent the outcome in a real-life setting. However, as the data were received from different centers they may be influenced by center-specific routines. Blood samples for response evaluation were mostly taken monthly, but at some centers every 6-8 week. This variation could affect TTP or PFS why we consider TTNT to be a more reliable end point.
It is important to emphasize the retrospective nature of the study. We have no data on whether the relapse and indication for start of second-line treatment was symptomatic (CRAB) or merely biochemical (clear increase of M-protein level). However, we believe that the high number of patients studied, at least to some extent, distribute the indications for treatment evenly between the groups. Physician's choice-and patient's preferencesdecided which second-line treatment was offered and given to the individual patient. However, the baseline characteristics were well balanced between the three patient groups, with the exceptions of hemoglobin levels and patient age. Hemoglobin levels were somewhat higher in the group that underwent a second ASCT, but it seems unlikely that this difference should have a significant impact on the outcome parameters presented. Patients receiving a second ASCT were somewhat younger than those in the other two groups. This might be because of the physician´s choice to expose younger patients, rather than elderly ones, to more intensive treatment. However, the difference in median age was rather small (median age 54 and 59 years respectively for patients receiving a second ASCT and regimens including novel therapies; Table 1 ). There was no significant difference in TTNT1 between the three groups.
Only 20% of the patients in our cohort were re-treated with a second ASCT in first relapse. This might be owing to the treating physician's belief that modern MM treatment including novel drugs is as good or even better than a second ASCT. However, we do not think that this would introduce serious bias in the comparison between the groups, this assumption being based on the relatively even distribution of prognostic parameters (see above).
Our findings are supported by a previous prospective study showing longer PFS for patients undergoing a second ASCT in A second ASCT at relapse prolongs survival M Grövdal et al relapse compared with the treatment with cyclophosphamide alone. 19 Our study in addition indicates that novel drugs alone are less effective than ASCT added to novel and/or conventional drugs as a consolidation.
Thus, we conclude that a second ASCT in first relapse after a previous ASCT results in significantly better responses and significantly better TTP, TTNT and OS compared with any other therapy weather it includes novel drugs or not. A second ASCT should therefore be recommended as first choice for eligible patients. A second ASCT at relapse prolongs survival M Grövdal et al
